DECREASED EXPRESSION OF ADHESION MOLECULES IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS OF PATIENTS TREATED WITH IBRUTINIB

被引：0
|
作者：
Guarini, A. [1 ,2 ]
De Propris, M. S. [1 ]
Milani, M. L. [1 ]
Intoppa, S. [1 ]
Faraone, S. [1 ]
Peragine, N. [1 ]
Mariglia, P. [1 ]
Puzzolo, M. C. [1 ]
Mauro, F. R. [1 ]
Del Giudice, I. [1 ]
Foa, R. [1 ]
机构：
[1] Sapienza Univ, Dept Cellular Biotechnol & Hematol, Rome, Italy
[2] Sapienza Univ, Dept Mol Med, Hematol, Rome, Italy
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E989
引用
收藏
页码：406 / 406
页数：1
相关论文
共 50 条
  • [1] Hypertension in ibrutinib-treated patients with chronic lymphocytic leukemia (CLL)
    Roeker, Lindsey
    Yazdy, Maryam
    Gashonia, Lisa
    Narkhede, Mayur
    Goodfriend, Julie
    Rhodes, Joanna
    Kennard, Kaitlin
    Dorsey, Colleen
    Sarmasti, Lisa
    Calivo, Kathleen
    Carver, Joseph
    Schuster, Steven
    Cheson, Bruce D.
    Mato, Anthony
    LEUKEMIA & LYMPHOMA, 2020, 61 : 55 - 56
  • [2] Pharmacokinetics (PK) of ibrutinib in patients with chronic lymphocytic leukemia (CLL)
    Sukbuntherng, Juthamas
    Jejurkar, Purvi
    Chan, Stephen
    Tran, Anh L.
    Moussa, Davina
    James, Danelle Frances
    Loury, David
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] HYPOGAMMAGLOBULINEMIA AND INFECTIONS IN IBRUTINIB-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: A PROSPECTIVE STUDY
    Cassin, R.
    Noto, A.
    Silvestris, I.
    Barbieri, M.
    Cappello, E.
    Lonati, S.
    Baldini, L.
    Neri, A.
    Reda, G.
    HAEMATOLOGICA, 2019, 104 : 38 - 38
  • [4] Adhesion molecules expression in cells from stage II(S) and stages 0 and I chronic lymphocytic leukemia (CLL) patients
    Bairey, O
    Zimra, Y
    Rabizadeh, E
    Shaklai, M
    BLOOD, 2001, 98 (11) : 281B - 281B
  • [5] Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia
    Roeker, Lindsey E.
    Yazdy, Maryam Sarraf
    Rhodes, Joanna
    Goodfriend, Julie
    Narkhede, Mayur
    Carver, Joseph
    Mato, Anthony
    JAMA NETWORK OPEN, 2019, 2 (12) : E1916326
  • [6] Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)
    Komarova, Natalia L.
    Burger, Jan A.
    Wodarz, Dominik
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (38) : 13906 - 13911
  • [7] Immunophenotyping of Peripheral Blood Cells in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
    Stephan, Pierre
    Bouherrou, Khaled
    Guillermin, Yann
    Michallet, Anne-Sophie
    Grinberg-Bleyer, Yenkel
    CELLS, 2024, 13 (17)
  • [8] Achievement of complete remission (CR) as an endpoint for patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib.
    Strati, Paolo
    Sivina, Mariela
    Kim, Ekaterina
    Keating, Michael J.
    Wierda, William G.
    Ferrajoli, Alessandra
    Kantarjian, Hagop M.
    Estrov, Zeev
    Jain, Nitin
    Thompson, Philip A.
    Burger, Jan Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] The Amount of Apoptosis Predicts Outcome in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL)
    Del Poeta, Giovanni
    Postorino, Massimiliano
    Pozzo, Federico
    Del Principe, Maria Ilaria
    Santinelli, Enrico
    Bomben, Riccardo
    Biagi, Annalisa
    Buccisano, Francesco
    Rossi, Francesca Maria
    Venditti, Adriano
    de Fabritiis, Paolo
    Cantonetti, Maria
    Amadori, Sergio
    Gattei, Valter
    Arcese, William
    BLOOD, 2018, 132
  • [10] Comprehensive Cardiac Testing in Asymptomatic Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib
    Itsara, Andy
    Sun, Clare
    Ahn, Inhye E.
    Soto, Susan
    Rosing, Douglas
    Haigney, Mark
    Wiestner, Adrian
    BLOOD, 2022, 140 : 4169 - 4170
12345